primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

van Akkooi AC, Kicinski M, Govaerts AS, Hauschild A, Rutkowski P, Arenberger P, Ascierto PA, Tomczak P, Quereux G, De Galitiis F, Dutriaux C, Gebhardt C, Kapiteijn E, Machet L, Berciano MG, Del Vecchio M, Jalving M, Jouary T, Krajsova I, Matkovic S, Merelli B, Mortier L, Pagès-Laurent PL, Palmieri G, Pracht M, Vantuchova Y, Massi D, Elaut N, de Schaetzen G, Nuyens S, Jha N, Klauck I, Sansas B, Vedovato JC, Lorigan PC, Long GV, Eggermont AM, Mandala M.

Open source

DOI: 10.1016/j.ejca.2026.116951
Published: 2026-07-21
Container: Eur J Cancer
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.116951,
  title = {primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.},
  author = {van Akkooi AC and  Kicinski M and  Govaerts AS and  Hauschild A and  Rutkowski P and  Arenberger P and  Ascierto PA and  Tomczak P and  Quereux G and  De Galitiis F and  Dutriaux C and  Gebhardt C and  Kapiteijn E and  Machet L and  Berciano MG and  Del Vecchio M and  Jalving M and  Jouary T and  Krajsova I and  Matkovic S and  Merelli B and  Mortier L and  Pagès-Laurent PL and  Palmieri G and  Pracht M and  Vantuchova Y and  Massi D and  Elaut N and  de Schaetzen G and  Nuyens S and  Jha N and  Klauck I and  Sansas B and  Vedovato JC and  Lorigan PC and  Long GV and  Eggermont AM and  Mandala M.},
  year = {2026},
  journal = {Eur J Cancer},
  doi = {10.1016/j.ejca.2026.116951},
  url = {https://doi.org/10.1016/j.ejca.2026.116951}
}

RIS

TY  - JOUR
TI  - primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.
AU  - van Akkooi AC
AU  -  Kicinski M
AU  -  Govaerts AS
AU  -  Hauschild A
AU  -  Rutkowski P
AU  -  Arenberger P
AU  -  Ascierto PA
AU  -  Tomczak P
AU  -  Quereux G
AU  -  De Galitiis F
AU  -  Dutriaux C
AU  -  Gebhardt C
AU  -  Kapiteijn E
AU  -  Machet L
AU  -  Berciano MG
AU  -  Del Vecchio M
AU  -  Jalving M
AU  -  Jouary T
AU  -  Krajsova I
AU  -  Matkovic S
AU  -  Merelli B
AU  -  Mortier L
AU  -  Pagès-Laurent PL
AU  -  Palmieri G
AU  -  Pracht M
AU  -  Vantuchova Y
AU  -  Massi D
AU  -  Elaut N
AU  -  de Schaetzen G
AU  -  Nuyens S
AU  -  Jha N
AU  -  Klauck I
AU  -  Sansas B
AU  -  Vedovato JC
AU  -  Lorigan PC
AU  -  Long GV
AU  -  Eggermont AM
AU  -  Mandala M.
PY  - 2026
JO  - Eur J Cancer
DO  - 10.1016/j.ejca.2026.116951
UR  - https://doi.org/10.1016/j.ejca.2026.116951
ER  -

APA

AC, V. A., M, K., AS, G., A, H., P, R., P, A., PA, A., P, T., G, Q., F, D. G., C, D., C, G., E, K., L, M., MG, B., M, D. V., M, J., T, J., I, K., S, M., B, M., L, M., PL, P., G, P., M, P., Y, V., D, M., N, E., G, D. S., S, N., N, J., I, K., B, S., JC, V., PC, L., GV, L., AM, E., & M., M. (2026). primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.. Eur J Cancer. https://doi.org/10.1016/j.ejca.2026.116951

Source records

europe-pmc · retrieved 2026-09-25T09:21:00.618Z